{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:27:42Z","timestamp":1776742062979,"version":"3.51.2"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ymgmr.2022.100930","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T05:21:29Z","timestamp":1666761689000},"page":"100930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme"],"prefix":"10.1016","volume":"33","author":[{"given":"Andreas","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Pfrimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben J.","family":"Boado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Pardridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2022.100930_bb0005","first-page":"1906","article-title":"Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease)","volume":"2013","author":"Hawkins-Salsbury","year":"1832","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgmr.2022.100930_bb0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.braindev.2008.12.008","article-title":"Towards understanding the neuronal ceroid lipofuscinoses","volume":"31","author":"Kohlschutter","year":"2009","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2021.04.002","article-title":"Management of CLN1 disease: international clinical consensus","volume":"120","author":"Augustine","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0020","doi-asserted-by":"crossref","first-page":"23212","DOI":"10.1016\/S0021-9258(17)31641-1","article-title":"Molecular cloning and expression of palmitoyl-protein thioesterase","volume":"269","author":"Camp","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ymgme.2009.12.002","article-title":"Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis","volume":"99","author":"Lu","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2015.05.005","article-title":"Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis","volume":"116","author":"Lu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/B978-0-12-396962-0.00011-2","article-title":"Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier","volume":"503","author":"Pardridge","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial","volume":"13","author":"Giugliani","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0050","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0060","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1038\/s41598-019-55136-4","article-title":"Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery","volume":"9","author":"Boado","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/mgme.1999.2809","article-title":"A rapid fluorogenic palmitoyl-protein thioesterase assay: pre- and postnatal diagnosis of INCL","volume":"66","author":"van Diggelen","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0070","doi-asserted-by":"crossref","DOI":"10.1007\/s11011-021-00893-3","article-title":"Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid Metab","author":"Sato","year":"2022","journal-title":"Brain Dis."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","article-title":"Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis","volume":"18","author":"Mole","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0080","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2022.100930_bb0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pediatrneurol.2020.04.018","article-title":"Intracerebroventricular cerliponase alfa for neuronal ceroid Lipofuscinosis type 2 disease: clinical practice considerations from US","volume":"110","author":"de Los Reyes","year":"2020","journal-title":"Clin. Pediatr. Neurol."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:51Z","timestamp":1762001571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":17,"alternative-id":["S2214426922000908"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100930","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100930"}}